Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study of TG6002 (VV TK-RR-FCU1) Administered by Intravenous (IV) Infusions in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Gastro-intestinal (GI) Tumors.

NCT03724071 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT03724071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03724071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study of TG6002 (VV TK-RR-FCU1) Administered by Intravenous (IV) Infusions in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Gastro-intestinal (GI) Tumors.
Lead sponsor
Transgene
Phase
Phase 1/2
Overall status
Terminated
Start date
October 16, 2018
Completion date
February 23, 2023
Enrollment
51 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasm, digestive system neoplasm